HCP Live June 5, 2024
Tim Smith

The VIO Skin Platform by Enspectra Health was designed to assess lesions indicating either basal cell carcinoma or squamous cell carcinoma.

An announcement by Enspectra Health, a company known for its focus on health technology, indicated that the US Food and Drug Administration (FDA) awarded a Breakthrough Device Designation to Enspectra’s advanced artificial intelligence (AI)-powered ‘VIO Skin Platform’ (VIO).1

The company’s AI platform was designed with the purpose of assessing lesions that could indicate the presence of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) among individuals deemed to be high-risk. These prevalent forms of skin cancer remain an issue for many such patients and early identification can be crucial, especially given the reported delays in screening appointments that...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Medical Devices, Technology
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article